Barbara Gayle Duncan, Chief Financial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 1,054 shares at $159.04 ($172K) on 2015-10-02, disclosed to the SEC on 2015-10-05.
Scheduled sale ($172k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $163.39 | 1,000 | $163K | 95.0% |
| 2 | $159.04 | 54 | $9K | 5.0% |
| Total | $163.17 avg | 1,054 | $172K | 100% |
| Filing → |
| JNCE | SELL | 2018-01-29 | $100K | — | Filing → |
| GNMX | BUY | 2017-10-18 | $150K | — | Filing → |
| ICPT | SELL | 2016-10-05 | $24K | — | Filing → |